Standard BioTools Signs New Agreement to Sell Mass Cytometry Unit

Key Facts

1Standard BioTools entered into a new purchase agreement with Element Biosystems, a subsidiary of GMT Venture.

2The decision followed the company's determination that GMT Venture's unsolicited acquisition proposal was superior.

Standard BioTools entered into a new purchase agreement with Element Biosystems, a subsidiary of GMT Venture, for the sale of its Mass Cytometry business. GlobeNewswire reported that the decision followed the company's determination that an unsolicited acquisition proposal from GMT Venture was superior to previous arrangements.

LAB closed at $0.7133 on September 29, 2026, with the stock reaching a day high of $0.7343 and a low of $0.7099 during that session. The shift in divestment strategy highlights the company's focus on securing improved terms for its business unit disposal.